Thromboprophylaxis for venous thromboembolism prevention in hospitalized patients with cirrhosis: Guidance from the SSC of the ISTH
- PMID: 35948998
- DOI: 10.1111/jth.15829
Thromboprophylaxis for venous thromboembolism prevention in hospitalized patients with cirrhosis: Guidance from the SSC of the ISTH
Abstract
Hospital-associated venous thromboembolism (HA-VTE) is a major cause of morbidity and mortality and is internationally recognized as a significant patient safety issue. While cirrhosis was traditionally considered to predispose to bleeding, these patients are also at an increased risk of VTE, with an associated increase in mortality. Hospitalization rates of patients with cirrhosis are increasing, and decisions regarding thromboprophylaxis are complex due to the uncertain balance between thrombosis and bleeding risk. This is further accentuated by derangements of hemostasis in patients with cirrhosis that are often considered contraindications to pharmacological thromboprophylaxis. Due to the strict inclusion and exclusion criteria of seminal studies of VTE risk assessment and thromboprophylaxis, there is limited data to guide decision making in this patient group. This guidance document reviews the incidence and risk factors for HA-VTE in patients with cirrhosis, outlines evidence to inform the use of thromboprophylaxis, and provides pragmatic recommendations on VTE prevention for hospitalized patients with cirrhosis. In brief, in hospitalized patients with cirrhosis: We suggest inclusion of portal vein thrombosis as a distinct clinically important endpoint for future studies. We recommend against the use of thrombocytopenia and/or prolongation of prothrombin time/international normalized ratio as absolute contraindications to anticoagulant thromboprophylaxis. We suggest anticoagulant thromboprophylaxis in line with local protocols and suggest low molecular weight heparin (LMWH) or fondaparinux over unfractionated heparin (UFH). In renal impairment, we suggest LMWH over UFH. For critically ill patients, we suggest case-by-case consideration of thromboprophylaxis. We recommend research to refine VTE risk stratification, and to establish the optimal dosing and duration of thromboprophylaxis.
Keywords: liver cirrhosis; liver diseases; prevention; thromboprophylaxis; venous thrombosis.
© 2022 International Society on Thrombosis and Haemostasis.
Similar articles
-
Evaluation of unfractionated heparin versus low-molecular-weight heparin and fondaparinux for pharmacologic venous thromboembolic prophylaxis in critically ill patients with cancer.J Thromb Haemost. 2018 Dec;16(12):2492-2500. doi: 10.1111/jth.14317. Epub 2018 Nov 15. J Thromb Haemost. 2018. PMID: 30347498
-
Prevention of VTE in nonsurgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.Chest. 2012 Feb;141(2 Suppl):e195S-e226S. doi: 10.1378/chest.11-2296. Chest. 2012. PMID: 22315261 Free PMC article.
-
Prevention of venous thromboembolism in hospitalized acutely ill medical patients: focus on the clinical utility of (low-dose) fondaparinux.Drug Des Devel Ther. 2013 Sep 16;7:973-80. doi: 10.2147/DDDT.S38042. eCollection 2013. Drug Des Devel Ther. 2013. PMID: 24068866 Free PMC article. Review.
-
Safety and efficacy of pharmacological thromboprophylaxis for hospitalized patients with cirrhosis: a single-center retrospective cohort study.J Thromb Haemost. 2015 Jul;13(7):1245-53. doi: 10.1111/jth.13000. Epub 2015 Jun 15. J Thromb Haemost. 2015. PMID: 25955079 Free PMC article.
-
Anticoagulation for stroke prevention in atrial fibrillation and treatment of venous thromboembolism and portal vein thrombosis in cirrhosis: guidance from the SSC of the ISTH.J Thromb Haemost. 2024 Sep;22(9):2653-2669. doi: 10.1016/j.jtha.2024.05.023. Epub 2024 May 31. J Thromb Haemost. 2024. PMID: 38823454 Review.
Cited by
-
Effectiveness, safety, and costs of thromboprophylaxis with enoxaparin or unfractionated heparin in inpatients with obesity.Front Cardiovasc Med. 2023 Jun 16;10:1163684. doi: 10.3389/fcvm.2023.1163684. eCollection 2023. Front Cardiovasc Med. 2023. PMID: 37396589 Free PMC article.
-
Managing a Prospective Liver Transplant Recipient on the Waiting List.J Clin Exp Hepatol. 2024 Jan-Feb;14(1):101203. doi: 10.1016/j.jceh.2023.06.003. Epub 2023 Jun 14. J Clin Exp Hepatol. 2024. PMID: 38076359 Free PMC article. Review.
-
Surgical risk stratification in patients with cirrhosis.Hepatol Int. 2024 Jun;18(3):876-891. doi: 10.1007/s12072-024-10644-y. Epub 2024 Mar 12. Hepatol Int. 2024. PMID: 38472607 Free PMC article. Review.
-
Effectiveness, Safety, and Costs of Thromboprophylaxis with Enoxaparin or Unfractionated Heparin Among Medical Inpatients With Chronic Obstructive Pulmonary Disease or Heart Failure.J Health Econ Outcomes Res. 2024 Feb 20;11(1):44-56. doi: 10.36469/001c.92408. eCollection 2024. J Health Econ Outcomes Res. 2024. PMID: 38390025 Free PMC article.
-
Limitations of venous thromboembolism risk assessment models in medical patients: Response to "Unmet definitions in thromboprophylaxis for hospitalized medical patients: An appraisal for the need of recommendation".Res Pract Thromb Haemost. 2023 Feb 15;7(1):100027. doi: 10.1016/j.rpth.2022.100027. eCollection 2023 Jan. Res Pract Thromb Haemost. 2023. PMID: 36970746 Free PMC article. No abstract available.
References
REFERENCES
-
- Jha AK, Larizgoitia I, Audera-Lopez C, Prasopa-Plaizier N, Waters H, Bates DW. The global burden of unsafe medical care: analytic modelling of observational studies. BMJ Qual Saf. 2013;22(10):809-815.
-
- Samama MM, Cohen AT, Darmon J-Y, et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. N Engl J Med. 1999;341(11):793-800.
-
- Leizorovicz A, Cohen AT, Turpie AG, et al. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation. 2004;110(7):874-879.
-
- Gu W, Hortlik H, Erasmus H-P, et al. Trends and the course of liver cirrhosis and its complications in Germany: Nationwide population-based study (2005 to 2018). Lancet Reg Health Eur. 2022;12:100240.
-
- Office for Health Improvements and Disparities. Official Statistics: Liver disease profiles, January 2022. 2022. Available at: https://wwwgovuk/government/statistics/liver-disease-profiles-january-2022-update/liver-disease-profiles-january-2022-update2022
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical